BIA-ALCL
OtherObservational : no intervention
Recruiting
NCT Number: NCT04220970
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.
Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).
This registry is opened in France and in Belgium
Recruiting
Interested in participating?
Request InfoKey information
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
Primary location
A. Z. Sint-Jan Brugge-Oostende AV, Bruges, Belgium
Loading trial locations.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult patients with an anaplastic large cell lymphoma associated with breast implants
Exclusion criteria
-
Treatment and study plan
Primary outcomes
-
Overall response
Time frame: 13 years
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
The Lymphoma Academic Research Organisation
Other
Registry information
Important dates
- Study start
- 2017
- Primary completion
- 2032
- Study completion
- 2032
- First posted
- Jan 7, 2020
- Registry last updated
- Jan 14, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.